https://doi.org/10.55788/5695aeff
The single-centre, randomised GLORIOUS trial with a 2-by-2 design tested a restrictive versus a liberal oxygenation strategy as well as the glucagon-like peptide-1 (GLP-1) agonist exenatide versus a placebo among patients who underwent CPB-assisted heart surgery. Dr Sebastian Wiberg (Rigshospitalet Copenhagen University, Denmark) discussed the findings regarding the oxygenation strategy [1]. “Application of CPB is known to cause organ injury,” said Dr Wiberg, “and oxidative stress is part of the mechanism leading to these injuries.”
The trial enrolled 1,389 participants who underwent CPB-assisted coronary artery bypass grafting (CABG) and/or aortic valve replacement. Participants were randomised 1:1 to a restrictive oxygenation strategy (FiO2 50%) during CPB and the first hour after weaning from CPB or to a liberal oxygenation strategy (FiO2 100%). The primary endpoint was the time to first occurrence of a composite of death, stroke, renal failure, or heart failure. “In case of an oxygen saturation level <92% for more than 30 seconds, FiO2 was increased to reach a saturation level of at least 92%,” added Dr Wiberg.
As expected, the arterial oxygen partial pressure was significantly higher in the liberal oxygenation arm than in the restricted oxygenation arm (210 mmHg vs 83 mmHg; P<0.001). However, after a median follow-up of 5.9 years, the authors did not see a difference between the 2 strategies with respect to the primary endpoint (HR 1.00; 95% CI 0.81–1.30; P=0.92). Neither did Dr Wiberg and colleagues report significant differences between the study arms regarding the occurrence of adverse events. Surgical site infections were numerically but not significantly higher in the restricted oxygenation arm (3.2% vs 1.6%; P=0.05).
“In adult patients undergoing elective or sub-acute CPB-assisted CABG and/or aortic valve replacement, a restrictive oxygenation strategy during CPB and weaning did not reduce mortality or morbidity from renal failure, stroke, or heart failure, as compared with a liberal oxygenation strategy,” concluded Dr Wiberg.
- Wiberg S, et al. Restrictive vs liberal oxygenation in CPB-assisted heart surgery. LBS.04, AHA Scientific Sessions 2024, 16–18 November, Chicago, USA.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« GLORIOUS: GLP-1 agonist did not meet primary endpoint in CABG Next Article
CLEAR Outcomes: Bempedoic acid reduces MACE and MALE in patients with PAD »
« GLORIOUS: GLP-1 agonist did not meet primary endpoint in CABG Next Article
CLEAR Outcomes: Bempedoic acid reduces MACE and MALE in patients with PAD »
Table of Contents: AHA 2024
Featured articles
Ablation for Arrhythmias
PROMPT-AF: Novel ablation strategy improves outcomes for persistent AF
ARREST-AF: The true impact of risk factor management on AF recurrence after ablation
VANISH2: Antiarrhythmic drug therapy or catheter ablation in prior myocardial infarction complicated by ventricular tachycardia?
OPTION: LAAC over OAC after ablation in patients with AF and increased stroke risk
Head-to-head: Cryoballoon vs radiofrequency ablation in persistent AF
Novel Treatment Options in Heart Failure
Will myeloperoxidase inhibition benefit patients with heart failure?
Is intranasal bumetanide a viable diuretic option in congestive HF?
REALIZE-K: MRA treatment optimisation in HFrEF plus hyperkalaemia
SUMMIT: Tirzepatide reduces cardiovascular events in HFpEF plus obesity
CAD, PAD, and Valvular Heart Disease
CLEAR Outcomes: Bempedoic acid reduces MACE and MALE in patients with PAD
GLORIOUS: Restrictive versus liberal oxygenation during CPB-assisted surgery
GLORIOUS: GLP-1 agonist did not meet primary endpoint in CABG
CLEAR SYNERGY: Can routine spironolactone improve post-MI outcomes?
ENBALV: Edoxaban or warfarin as anticoagulant after bioprosthetic valve replacement?
Prospects in Prevention
ZODIAC: Can we improve lipid-lowering strategies in ACS?
KRAKEN: Encouraging phase 2 results of Lp(a)-lowering muvalaplin
Reconditioned pacemakers may save lives in low/middle-income countries
Novel small-interfering RNA effectively reduced Lp(a) in phase 2
Impactful Hypertension Strategies
Comparing dual antihypertensive combination therapies in a South Asian population
BPROAD: Intensive or standard BP treatment strategy in type 2 diabetes?
Innovative Studies in Heart Disease
Promising results for CRISPR-based therapy in ATTR-CM
NUDGE-FLU: Effect of science-informed letters on influenza vaccination rates
Related Articles
February 3, 2025
Promising results for CRISPR-based therapy in ATTR-CM
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
